<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594591</url>
  </required_header>
  <id_info>
    <org_study_id>PI 17/01479</org_study_id>
    <nct_id>NCT03594591</nct_id>
  </id_info>
  <brief_title>Changes in the Retinal and Carotid Microcirculation After Restoring Normoglycemia in Patients With Type 2 Diabetes</brief_title>
  <acronym>OCTAUS-T2D</acronym>
  <official_title>Changes in the Retinal and Carotid Microcirculation After Restoring Normoglycemia in Patients With Type 2 Diabetes (OCTAUS-T2D Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut d'Investigacions Biomèdiques August Pi i Sunyer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective and observational study in patients with type two diabetes. The study
      hypothesis is that chronic hyperglycemia causes an increase in the microcirculation on the
      carotid artery wall and retina, evaluated by angio-OCT. Furthermore, the reestablishment of
      normoglycemia would decrease this microcirculation, which could trigger hypoxic and ischemic
      changes, accelerating preclinical atherosclerosis. The study goal is to describe the
      microangiopathy in both territories in patients with type two diabetes and chronic
      hyperglycemia, and to evaluate changes after the reestablishment of normoglycemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective and observational study in patients with type two diabetes. The study
      hypothesis is that chronic hyperglycemia causes an increase in the microcirculation on the
      carotid artery wall (evaluating vasa vasorum by contrast-assessed carotid ultrasound) and
      retina (evaluated by angio-OCT). Furthermore, the reestablishment of normoglycemia would
      decrease this microcirculation, which could trigger hypoxic and ischemic changes,
      accelerating preclinical atherosclerosis. The primary outcome is to describe the
      microangiopathy in both territories in 20 patients with type two diabetes and chronic
      hyperglycemia (basal), and to evaluate the changes after the reestablishment of normoglycemia
      (at 1, 3 and 6 months). Additionally, clinical, laboratory, diet and biomarkers will be
      evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in retinal microcirculation (perifoveal vessel density)</measure>
    <time_frame>0, 1, 3 and 6 months</time_frame>
    <description>Changes in perifoveal vessel density, OCTA images will be processed to obtain vascular density measurements in this area (mm-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in arterial wall microcirculation (vasa-vasorum density)</measure>
    <time_frame>0, 3 and 6 months</time_frame>
    <description>Changes vasa-vasorum (VV) density, VV signal as the ratio of the contrast agent signal of the VV and that of the lumen of the artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in retinal microcirculation (Parafoveal vessel density )</measure>
    <time_frame>0, 1, 3 and 6 months</time_frame>
    <description>OCTA images will be processed to obtain vascular density measurements in this area (mm-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in retinal microcirculation (Total Avascular Area )</measure>
    <time_frame>0, 1, 3 and 6 months</time_frame>
    <description>OCTA images will be processed to obtain total avascular area measurements (mm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in retinal microcirculation (Foveal Avascular Area)</measure>
    <time_frame>0, 1, 3 and 6 months</time_frame>
    <description>OCTA images will be processed to obtain foveal avascular zone area measurements (mm2)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Microangiopathy</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Carotid Atherosclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidiabetic treatment by usual care</intervention_name>
    <description>Observation of changes in the microcirculation after optimization of antidiabetic therapy by usual care.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type two diabetes with chronic hyperglycemia (HbA1c &gt;9%) in who a swift and
        maintained improvement in glycemic control is expected, as a consequence of the
        antidiabetic treatment decided by usual care owing to the clinical situation. Patients with
        new diagnose of type two diabetes who start treatment (insulin and non-insulin drugs) in
        which a long-evolution diabetes is suspected will also be candidates.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with type two diabetes with chronic hyperglycemia (HbA1c &gt;9%) in who a swift
             and maintained improvement in glycemic control is expected, as a consequence of the
             antidiabetic treatment decided by usual care owing to the clinical situation.

             This treatment will include, in many cases, albeit not always, insulin (basal,
             basal-plus, mixes, or multiple doses). The usual clinical scenario will be failure to
             non-insulin antidiabetic drugs or to combined treatment (basal insulin and non-insulin
             drugs). Patients with new diagnose of type two diabetes who start treatment (insulin
             and non-insulin drugs) in which a long-evolution diabetes is suspected will also be
             candidates.

          2. Caucasian and age between 35 and 75 years.

          3. Informed consent by the patient or legal tutor.

        Exclusion Criteria:

          1. Previous history of carotid territory interventionism (stent o endarterectomy).

          2. Presence of carotid plaques in the first centimetre of the posterior wall of the
             common carotid artery.

          3. Ophtalmologic: Proliferative diabetic retinopathy and/or diabetic macular oedema,
             retinal photocoagulation, intravitreous therapy and/or vitreo-retinal surgery, myopia
             of &gt;6 diopters, history of non-diabetic vascular retinopathy.

          4. Stage 4 chronic kidney disease (estimated glomerular filtration &lt;30 ml/min/1,73m2),
             organ transplant, HIV chronic infection, active tuberculosis, active malaria, chronic
             b or C hepatitis, cirrhosis or intestinal inflammatory disease.

          5. Current pregnancy or breastfeeding, o gestational desire in the following two years.

          6. History of alcohol or drug dependence (except for caffeine and nicotine) in the former
             5 years, active depression or psychiatric disease, dementia, presence of another
             chronic or debilitating disease with short life-expectancy, institutionalization or
             severe disability.

          7. Presence of contraindications for the use of ecographic contrast.

          8. Current Participation in another study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilio Ortega, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilio Ortega, MD, PhD</last_name>
    <phone>+34932279846</phone>
    <email>eortega1@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Ortega, MD, PhD</last_name>
      <phone>+34932279846</phone>
      <email>eortega1@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Antonio J Amor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Figueras, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosa Gilabert, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Montserrat Cofán, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Boswell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mireia Hereu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleix Sala-Vila, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.</citation>
    <PMID>18539917</PMID>
  </reference>
  <reference>
    <citation>Sanahuja J, Alonso N, Diez J, Ortega E, Rubinat E, Traveset A, Alcubierre N, Betriu À, Castelblanco E, Hernández M, Purroy F, Arcidiacono MV, Jurjo C, Fernández E, Puig-Domingo M, Groop PH, Mauricio D. Increased Burden of Cerebral Small Vessel Disease in Patients With Type 2 Diabetes and Retinopathy. Diabetes Care. 2016 Sep;39(9):1614-20. doi: 10.2337/dc15-2671. Epub 2016 Jun 8.</citation>
    <PMID>27281772</PMID>
  </reference>
  <reference>
    <citation>Arcidiacono MV, Rubinat E, Borras M, Betriu A, Trujillano J, Vidal T, Mauricio D, Fernández E. Left carotid adventitial vasa vasorum signal correlates directly with age and with left carotid intima-media thickness in individuals without atheromatous risk factors. Cardiovasc Ultrasound. 2015 Apr 17;13:20. doi: 10.1186/s12947-015-0014-7.</citation>
    <PMID>25889409</PMID>
  </reference>
  <reference>
    <citation>Catalan M, Herreras Z, Pinyol M, Sala-Vila A, Amor AJ, de Groot E, Gilabert R, Ros E, Ortega E. Prevalence by sex of preclinical carotid atherosclerosis in newly diagnosed type 2 diabetes. Nutr Metab Cardiovasc Dis. 2015 Aug;25(8):742-8. doi: 10.1016/j.numecd.2015.04.009. Epub 2015 May 7.</citation>
    <PMID>26033395</PMID>
  </reference>
  <reference>
    <citation>Dimitrova G, Chihara E, Takahashi H, Amano H, Okazaki K. Author Response: Quantitative Retinal Optical Coherence Tomography Angiography in Patients With Diabetes Without Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1767. doi: 10.1167/iovs.17-21706.</citation>
    <PMID>28334376</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>July 20, 2018</last_update_submitted>
  <last_update_submitted_qc>July 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Emilio Ortega Martínez de Victoria</investigator_full_name>
    <investigator_title>Principal Investigator, Consultant Endocrinologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

